{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:02:28Z","timestamp":1786982548904,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tianeptine, an atypical antidepressant not approved in the United States, is readily purchased from unregulated markets such as the internet and gas stations. We became aware of a cluster of 34 patients in New Jersey who became ill following ingestion of the tianeptine containing-product Neptune\u2019s Fix, the rate of which (4.6 cases per month) far exceeded the background rate for this substance of 0.5 cases per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified tianeptine exposures reported to the New Jersey Poison Information and Education System (NJPIES) prior to June 2023 to determine the background rate of tianeptine exposure. From June 2023\u2013 February 2024 we prospectively surveilled tianeptine exposures reported to NJPIES, recorded demographic and clinical information, and recruited samples for testing. Six samples of the ingested products were obtained and analyzed using gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). Whole blood samples from two patients were tested for tianeptine and synthetic cannabinoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the period of interest, NJPIES received 41 exposure calls, with 37 reporting acute toxicity in 34 unique patients, two reporting chronic tianeptine use, and two reporting withdrawal. Among the 37 exposures resulting in acute toxicity, commonly reported effects included altered mental status, tachycardia, hypotension, and seizures. 43% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) were intubated, and 65% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) were admitted to the ICU. Analytical testing of six samples identified variable product composition, containing various xenobiotics including tianeptine, kava alkaloids, natural cannabinoids, and the synthetic cannabinoids MDMB-4en-PINACA and ADB-4en-PINACA. MDMB-4en-PINACA was detected in one of the two patient blood specimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These cases represent a marked increase in tianeptine exposures compared with the poison center\u2019s historical average. Analytical testing revealed variable product composition, including the presence of synthetic cannabinoids. Clinicians should be aware that tianeptine containing products are widely available, unregulated, and can be adulterated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13181-025-01068-7","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:53:38Z","timestamp":1742302418000},"page":"253-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An Outbreak of Synthetic Cannabinoid-Adulterated Tianeptine Products in New Jersey \u2013 Case Series"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6524-4263","authenticated-orcid":false,"given":"Christopher J.","family":"Counts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A.","family":"Cerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Krotulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Greller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane P.","family":"Calello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.rpsm.2018.09.002","volume":"12","author":"C Alamo","year":"2019","unstructured":"Alamo C, Garc\u00eda-Garcia P, Lopez-Mu\u00f1oz F, Zaragoz\u00e1 C. Tianeptine, an atypical Pharmacological approach to depression. Rev Psiquiatr Salud Ment Engl Ed. 2019;12:170\u201386.","journal-title":"Rev Psiquiatr Salud Ment Engl Ed"},{"key":"1068_CR2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40122-023-00539-5","volume":"12","author":"AN Edinoff","year":"2023","unstructured":"Edinoff AN, Sall S, Beckman SP, Koepnick AD, Gold LC, Jackson ED, et al. Tianeptine, an antidepressant with opioid agonist effects: Pharmacology and abuse potential, a narrative review. Pain Ther. 2023;12:1121\u201334.","journal-title":"Pain Ther"},{"key":"1068_CR3","unstructured":"US Food & Drug Administration. Tianeptine Products Linked to Serious Harm, Overdoses, Death [Internet]. FDA. FDA. 2022 [cited 2024 Jan 5]. Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/tianeptine-products-linked-serious-harm-overdoses-death"},{"key":"1068_CR4","unstructured":"US Food & Drug Administration. Tianeptine in Dietary Supplements [Internet]. FDA. FDA. 2023 [cited 2024 Jan 5]. Available from: https:\/\/www.fda.gov\/food\/dietary-supplement-ingredient-directory\/tianeptine-dietary-supplements"},{"key":"1068_CR5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.15585\/mmwr.mm6730a2","volume":"67","author":"T El Zahran","year":"2018","unstructured":"El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, et al. Characteristics of Tianeptine exposures reported to the National poison data System \u2014 United States, 2000\u20132017. MMWR Morb Mortal Wkly Rep. 2018;67:815\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1068_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/15563650.2020.1781151","volume":"59","author":"W Rushton","year":"2021","unstructured":"Rushton W, Whitworth B, Brown J, Kurz M, Rivera J. Characteristics of Tianeptine effects reported to a poison control center: a growing threat to public health. Clin Toxicol. 2021;59:152\u20137.","journal-title":"Clin Toxicol"},{"key":"1068_CR7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15585\/mmwr.mm7304a5","volume":"73","author":"CJ Counts","year":"2024","unstructured":"Counts CJ, Spadaro AV, Cerbini TA, Krotulski AJ, Greller HA, Nelson LS, et al. Notes from the field: cluster of severe illness from Neptune\u2019s fix Tianeptine linked to synthetic Cannabinoids - New Jersey, June-November 2023. MMWR Morb Mortal Wkly Rep. 2024;73:89\u201390.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1068_CR8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/1556-4029.14184","volume":"65","author":"AJ Krotulski","year":"2020","unstructured":"Krotulski AJ, Varnum SJ, Logan BK. Sample mining and data mining: combined Real-Time and retrospective approaches for the identification of emerging novel psychoactive substances. J Forensic Sci. 2020;65:550\u201362.","journal-title":"J Forensic Sci"},{"key":"1068_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","volume":"15","author":"BS McEwen","year":"2010","unstructured":"McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, et al. Toxic leukoencephalopathy associated with Tianeptine Misuse \u2014 California, 2017. Mol Psychiatry. 2010;15:237\u201349.","journal-title":"Mol Psychiatry"},{"key":"1068_CR10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/j.1552-4604.1988.tb05726.x","volume":"28","author":"A Dresse","year":"1988","unstructured":"Dresse A, Rosen JM, Brems H, Masset H, Defrance R, Salvadori C. Influence of food on Tianeptine and its main metabolite kinetics. J Clin Pharmacol. 1988;28:1115\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1068_CR11","doi-asserted-by":"crossref","unstructured":"Algorta J, Dominguez A, Tianeptine. New description of the mechanism of action and change of technical data sheet. Rev Psiquiatr Salud Ment Engl Ed. 2021;14:70\u20131.","DOI":"10.1016\/j.rpsmen.2021.03.002"},{"key":"1068_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pharmtox-031122-113758","volume":"63","author":"R Roque-Bravo","year":"2023","unstructured":"Roque-Bravo R, Silva RS, Malheiro RF, Carmo H, Carvalho F, Da Silva DD, et al. Synthetic cannabinoids: A Pharmacological and toxicological overview. Annu Rev Pharmacol Toxicol. 2023;63:187\u2013209.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1068_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mi.11.1.6","volume":"11","author":"KA Seely","year":"2011","unstructured":"Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011;11:36\u201351.","journal-title":"Mol Interv"},{"key":"1068_CR14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bmc.2007.09.033","volume":"16","author":"JW Huffman","year":"2008","unstructured":"Huffman JW, Thompson ALS, Wiley JL, Martin BR. Synthesis and Pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008;16:322\u201335.","journal-title":"Bioorg Med Chem"},{"key":"1068_CR15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","volume":"376","author":"AJ Adams","year":"2017","unstructured":"Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. Zombie outbreak caused by the synthetic cannabinoid AMB-FUBINACA in new York. N Engl J Med. 2017;376:235\u201342.","journal-title":"N Engl J Med"},{"key":"1068_CR16","doi-asserted-by":"crossref","unstructured":"Moritz E, Austin C, Wahl M, DesLauriers C, Navon L, Walblay K et al. Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids \u2014 Illinois, March\u2013April. 2018. 2018.","DOI":"10.15585\/mmwr.mm6721a4"},{"key":"1068_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","volume":"373","author":"J Trecki","year":"2015","unstructured":"Trecki J, Gerona RR, Schwartz MD. Synthetic Cannabinoid\u2013Related illnesses and deaths. N Engl J Med. 2015;373:103\u20137.","journal-title":"N Engl J Med"},{"key":"1068_CR18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2215\/CJN.05690612","volume":"8","author":"GK Bhanushali","year":"2013","unstructured":"Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: A case series. Clin J Am Soc Nephrol. 2013;8:523\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1068_CR19","unstructured":"World Health Organization. Critical Review Report: MDMB-4-en-PINACA. 2020. Available online: [Internet]. 2020. Available from: https:\/\/www.who.int\/docs\/default-source\/controlled-substances\/43rd-ecdd\/mdmb-4en-pinaca-review-2020.pdf?sfvrsn=5cd6e97e6"},{"key":"1068_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/dta.2935","volume":"13","author":"AJ Krotulski","year":"2021","unstructured":"Krotulski AJ, Cannaert A, Stove C, Logan BK. The next generation of synthetic cannabinoids: detection, activity, and potential toxicity of pent-4en and but\u20103en analogues including MDMB\u20104en\u2010PINACA. Drug Test Anal. 2021;13:427\u201338.","journal-title":"Drug Test Anal"},{"key":"1068_CR21","unstructured":"Labs NMS, Discovery NPS. ADB-4en-PINACA, monograph (N-[1-carbamoyl-2,- 2-dimethyl-propyl]-1-pent-4-enyl-indazole-3- carboxamide). 2021. [Internet]. 2021. Available from: https:\/\/www.npsdiscovery.org\/wp-content\/uploads\/2021\/03\/ADB-4en-PINACA_030421_NMSLabs_Report.pdf"},{"key":"1068_CR22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/dta.3203","volume":"14","author":"R Kronstrand","year":"2022","unstructured":"Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB\u20104en\u2010PINACA and their detection in forensic toxicology casework and infused papers seized in prisons. Drug Test Anal. 2022;14:634\u201352.","journal-title":"Drug Test Anal"},{"key":"1068_CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11419-022-00643-9","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Han L, Yi L, Liu J, Qiu S, Gu J, et al. Newly emerging synthetic cannabinoid ADB-4en-PINACA: its identification and quantification in an authentic human hair sample by GC\u2013MS\/MS. Forensic Toxicol. 2023;41:173\u20138.","journal-title":"Forensic Toxicol"},{"key":"1068_CR24","doi-asserted-by":"crossref","first-page":"e2451951","DOI":"10.1001\/jamanetworkopen.2024.51951","volume":"7","author":"D Kuai","year":"2024","unstructured":"Kuai D, Rivera Blanco LE, Krotulski A, Walton S, Denn M, Kelly B, et al. Identification and health risks of an emerging means of drug use in correctional facilities. JAMA Netw Open. 2024;7:e2451951.","journal-title":"JAMA Netw Open"},{"key":"1068_CR25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/ADM.0000000000001003","volume":"16","author":"L Szczesniak","year":"2022","unstructured":"Szczesniak L, Sullivan R. Microdose induction of buprenorphine in a patient using Tianeptine. J Addict Med. 2022;16:736\u20138.","journal-title":"J Addict Med"},{"key":"1068_CR26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.9740\/mhc.2022.12.356","volume":"12","author":"M Markovic","year":"2022","unstructured":"Markovic M, Niwash D. Treatment of concurrent etizolam and Tianeptine withdrawal following accidental overdose. Ment Health Clin. 2022;12:356\u20139.","journal-title":"Ment Health Clin"},{"key":"1068_CR27","unstructured":"United States Food and Drug Administration. Urgent messgae from FDA to Trade Associations Regarding Neptune\u2019s Fix [Internet]. 2024. Available from: https:\/\/www.fda.gov\/media\/175628\/download"},{"key":"1068_CR28","unstructured":"New York Times. \u2018Gas-Station Heroin\u2019 Sold as Dietary Supplement Alarms Health Officials. N Y Times [Internet]. 2024; Available from: https:\/\/www.nytimes.com\/2024\/01\/10\/health\/gas-station-heroin-tianeptine-addiction.html"},{"key":"1068_CR29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/ADM.0000000000000342","volume":"11","author":"S Gupta","year":"2017","unstructured":"Gupta S, Wallace R, Sloshower J. Online sales of unscheduled pharmaceutical agents: A case report of Tianeptine use in the united States. J Addict Med. 2017;11:411\u20132.","journal-title":"J Addict Med"},{"key":"1068_CR30","unstructured":"US Food & Drug Administration. FDA warns consumers not to purchase or use Neptune\u2019s Fix or any tianeptine product due to serious risks. FDA [Internet]. 2024 [cited 2024 Sep 19]; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-not-purchase-or-use-neptunes-fix-or-any-tianeptine-product-due-serious-risks"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-025-01068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-025-01068-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-025-01068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:52:37Z","timestamp":1742968357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-025-01068-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s13181-025-01068-7","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data in this manuscript were previously presented at ACMT\u2019s Annual Scientific Meeting, Washington, D.C., 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous Presentation"}},{"value":"DC reports receipt of honoraria from St. Peter\u2019s University Hospital (New Jersey) for Pediatric Grand Rounds presentation, payment from the District Attorney of New York for expert testimony in a criminal case, support to Poison Center to defray costs of professional conference travel from the New Jersey Department of Health, and membership on the American College of Medical Toxicology Board of Trustees (through January 2023). HG reports receipt of honoraria from UpToDate for authored content and reimbursement from the Department of Emergency Medicine, Rutgers University, for travel to meetings. AK reports funding from the National Institute of Justice, U.S. Department of Justice, for sample analysis and salary. TC, CC, and AS reports receipt of reimbursement for travel expenses and conference fees from Rutgers University. SW, LN, BR, OH, and BL declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Intrest"}}]}}